

study are insufficient to state whether the risk of stent thrombosis is higher after crush stenting technique. To reduce the risk of thrombotic events, a more liberal use of glycoprotein IIb/IIIa inhibitors should be considered.¹⁵ Furthermore, strict adherence to dual antiplatelet treatment is necessary.¹⁶

Limitations

The present study had some limitations. Firstly, it was a retrospective study with a small sample size. The choice of stenting strategy and the decision to use kissing balloon post-dilatation were at the operator's discretion and were non-randomised. Secondly, not all patients underwent angiographic follow up. Thirdly, we are not completely certain whether all the restenotic lesions located at the ostium of the side branch were functionally important; for some of them a severe angiographic stenosis may have been considered sufficient for a repeat intervention. Despite these limitations, the efficacy of kissing balloon post-dilatation in reducing the rate of side branch restenosis appears clear and the two groups were very similar in terms of baseline characteristics.

Conclusions

In non-selected bifurcation lesions treated with DES, the restenosis rate remains relatively high in the side branch. Compared with the T stenting technique, crush stenting with kissing balloon post-dilatation is associated with a low rate of restenosis in the side branch. Kissing balloon post-dilatation is mandatory when this technique is used.

Authors' affiliations

L Ge*, I Iakovou, J Cosgrave, P Agostoni, F Airolidi, G M Sangiorgi, I Michev, A Chieffo, M Montorfano, M Carlino, N Corvaja, A Colombo, EMO Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy

*Also the Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

REFERENCES

- Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. *Circulation* 2004;**109**:1244-9.
- Colombo A, Stankovic G, Orlic D, et al. Modified T-stenting technique with crushing for bifurcation lesions: immediate results and 30-day outcome. *Catheter Cardiovasc Interv* 2003;**60**:145-51.
- Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. *N Engl J Med* 2004;**350**:221-31.
- Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. *JAMA* 2005;**293**:2126-30.
- Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. *Circulation* 2004;**109**:1930-2.
- Chieffo A, Bonizzoni E, Orlic D, et al. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. *Circulation* 2004;**109**:2732-6.
- Lefevre T, Louvard Y, Morice MC, et al. Stenting of bifurcation lesions: classification, treatments, and results. *Catheter Cardiovasc Interv* 2000;**49**:274-83.
- Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. *Circulation* 1999;**100**:1872-8.
- Yamashita T, Nishida T, Adamian MG, et al. Bifurcation lesions: two stents versus one stent: immediate and follow-up results. *J Am Coll Cardiol* 2000;**35**:1145-51.
- Assali AR, Teplitsky I, Hasdai D, et al. Coronary bifurcation lesions: to stent one branch or both? *J Invasive Cardiol* 2004;**16**:447-50.
- Al Suwaidi J, Berger PB, Rihal CS, et al. Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. *J Am Coll Cardiol* 2000;**35**:929-36.
- Tanabe K, Hoye A, Lemos PA, et al. Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. *Am J Cardiol* 2004;**94**:115-8.
- Pan M, de Lezo JS, Medina A, et al. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. *Am Heart J* 2004;**148**:857-64.
- Ormiston JA, Currie E, Webster MW, et al. Drug-eluting stents for coronary bifurcations: insights into the crush technique. *Catheter Cardiovasc Interv* 2004;**63**:332-6.
- The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. *Lancet* 1998;**352**:87-92.
- Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. *J Am Coll Cardiol* 2005;**45**:456-9.

Committee on Publication Ethics – Seminar 2006

9.30am–5pm Friday 10th March 2006, BMA House, London, UK

This year's seminar takes an international perspective and addresses publication ethics and research in several European countries and beyond, with interactive workshops on common ethical and editorial dilemmas. The manipulation of impact factors, and whether unethical, will also be considered.

The seminar is for editors, authors, and all those interested in increasing the standard of publication ethics. The seminar will include:

- Professor Michael Farthing – the Panel for Research Integrity (UK)
- Publication ethics and research in other countries, including those in Northern Europe, Turkey, and China
- Publication ethics in animal research
- Making the COPE website work for you – real time demonstration on how to use the website
- New indexing services
- Interactive workshops – common ethical and editorial dilemmas for editors
- Opportunities to network with other editors and share your experiences and challenges

The seminar is free for COPE members and £30.00 + VAT for non-members. Numbers are limited and early booking is advisable. For registrations or more information please contact the COPE Secretary at cope@bmjgroup.com or call 020-7383-6602

For more information on COPE see www.publicationethics.org.uk